China Grants Conditional Approval for US COVID-19 Treatment 'Lagevrio' Import
China Grants Conditional Approval for Oral COVID-19 Treatment
[Asia Economy Reporter Koo Chae-eun] The Chinese government has conditionally approved the import of the oral COVID-19 treatment drug 'Lagevrio' from the American pharmaceutical company Merck & Company (MSD).
According to Chinese media Xinjingbao on the 30th, the China National Medical Products Administration made this decision yesterday following the special drug approval procedure under the Drug Administration Law.
Lagevrio is a medication that induces virus elimination by being inserted in place of ribonucleic acid (RNA) during the replication process of the COVID-19 virus. It has been approved in various countries as a treatment mainly for patients with mild to moderate symptoms or those at high risk of progressing to severe illness.
In South Korea, emergency use approval was granted in March.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Labor-Management 'Performance Bonus Negotiations' Fail in Third Mediation... Union Says "General Strike to Proceed as Planned Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Xinjingbao mentioned that it will be used to treat COVID-19 infections in patients with high-risk factors for severe progression, such as old age, obesity or overweight, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease, and cancer.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
